These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 10977030)

  • 1. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
    Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
    Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
    Kapitza C; Heise T; Fishman RS; Shapiro DA; Gopalakrishnan V; Rave K; Bott S; Perera AD; Heinemann L
    Diabetes Technol Ther; 2004 Apr; 6(2):119-27. PubMed ID: 15117578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.
    Heinemann L; Weyer C; Rauhaus M; Heinrichs S; Heise T
    Diabetes Care; 1998 Nov; 21(11):1910-4. PubMed ID: 9802742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
    Rave K; Bott S; Heinemann L; Sha S; Becker RH; Willavize SA; Heise T
    Diabetes Care; 2005 May; 28(5):1077-82. PubMed ID: 15855570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of insulin absorption and insulin action.
    Heinemann L
    Diabetes Technol Ther; 2002; 4(5):673-82. PubMed ID: 12450450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes.
    Kim D; Mudaliar S; Chinnapongse S; Chu N; Boies SM; Davis T; Perera AD; Fishman RS; Shapiro DA; Henry R
    Diabetes Care; 2003 Oct; 26(10):2842-7. PubMed ID: 14514589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
    Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
    Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic/pharmacodynamic modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients.
    Landersdorfer CB; Jusko WJ
    Drug Metab Pharmacokinet; 2010; 25(5):418-29. PubMed ID: 20924141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
    Steiner S; Pfützner A; Wilson BR; Harzer O; Heinemann L; Rave K
    Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):17-21. PubMed ID: 11835120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.
    Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T
    Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
    Perera AD; Kapitza C; Nosek L; Fishman RS; Shapiro DA; Heise T; Heinemann L
    Diabetes Care; 2002 Dec; 25(12):2276-81. PubMed ID: 12453973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture.
    Weyer C; Heise T; Heinemann L
    Diabetes Care; 1997 Oct; 20(10):1612-4. PubMed ID: 9314644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
    Pettis RJ; Ginsberg B; Hirsch L; Sutter D; Keith S; McVey E; Harvey NG; Hompesch M; Nosek L; Kapitza C; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):435-42. PubMed ID: 21355718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin.
    ter Braak EW; Woodworth JR; Bianchi R; Cerimele B; Erkelens DW; Thijssen JH; Kurtz D
    Diabetes Care; 1996 Dec; 19(12):1437-40. PubMed ID: 8941480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous insulin infusion to simulate subcutaneous absorption. Bioavailability and metabolic sequelae.
    Watanabe RM; Vølund A; Bergman RN
    Diabetes Care; 1991 Nov; 14(11):1021-30. PubMed ID: 1797482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles.
    Rave K; Nosek L; Heinemann L; Gonzales C; Ernest CS; Chien J; Muchmore D
    Diabet Med; 2004 Jul; 21(7):763-8. PubMed ID: 15209771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-response relationship of oral insulin spray in healthy subjects.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Diabetes Care; 2005 Jun; 28(6):1353-7. PubMed ID: 15920051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.